# Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

> **NCT01946711** · PHASE1,PHASE2 · COMPLETED · sponsor: **Pari Pharma GmbH** · enrollment: 14 (actual)

## Conditions studied

- Rhinosinusitis
- Chronic Polyposis

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT01946711
- **Lead sponsor:** Pari Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-28
- **Primary completion:** 2020-02-03
- **Final completion:** 2021-06-21
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2022-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946711, "Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01946711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*